PEMDA-HN STUDY
Presented by Prof Nabil F. Saba (Winship Cancer Institute Emory University, Atlanta, USA)
The PEMDA Head and Neck trial investigates the efficacy of a STAT3 inhibitor. Previous studies have shown that STAT3 inhibition, when combined with PD-L1 inhibitors, yields promising results and good tolerability.
This trial is a signal-seeking study designed to evaluate the activity of the combination of the STAT3 inhibitor, danvatirsen, with pembrolizumab compared to pembrolizumab alone. The primary goal is to determine whether the combination therapy shows enough efficacy to justify progressing to a larger, more definitive trial.
References:
Posner M. et al, ASCO2024 abstract #TPS6113
